Abstract: The invention relates to a compound which is (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1, 8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl) butanoic acid (1:1) citrate salt, pharmaceutical compositions including such compound, and to the use of such compound in therapy, including in the treatment of a disease or condition for which an ?vJ36 integrin antagonist is indicated, and in particular idiopathic pulmonary fibrosis.

Abstract: The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.